Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.
Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA. Among patients with metastatic renal cell carcinoma (mRCC), serial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results